Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTXR NASDAQ:FLNA NASDAQ:INKT NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.59+2.5%$0.62$0.48▼$2.24$16.17M0.98586,237 shs44,405 shsFLNACassava Sciences$1.23$1.33$1.15▼$4.98$59.42M-0.73529,696 shs63,315 shsINKTMiNK Therapeutics$11.76+0.7%$11.53$7.01▼$76.00$58.57M0.47162,537 shs1,541 shsUPXIUpexi$0.88-0.1%$1.13$0.54▼$10.62$61.76M-0.294.22 million shs852,106 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals0.00%+6.41%+2.61%-33.18%-73.82%FLNACassava Sciences0.00%+2.50%-6.82%-28.90%-38.81%INKTMiNK Therapeutics0.00%+0.26%-1.68%+2.01%+69.84%UPXIUpexi0.00%+5.60%-7.11%-12.87%-73.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTXRCitius Pharmaceuticals$0.59+2.5%$0.62$0.48▼$2.24$16.17M0.98586,237 shs44,405 shsFLNACassava Sciences$1.23$1.33$1.15▼$4.98$59.42M-0.73529,696 shs63,315 shsINKTMiNK Therapeutics$11.76+0.7%$11.53$7.01▼$76.00$58.57M0.47162,537 shs1,541 shsUPXIUpexi$0.88-0.1%$1.13$0.54▼$10.62$61.76M-0.294.22 million shs852,106 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTXRCitius Pharmaceuticals0.00%+6.41%+2.61%-33.18%-73.82%FLNACassava Sciences0.00%+2.50%-6.82%-28.90%-38.81%INKTMiNK Therapeutics0.00%+0.26%-1.68%+2.01%+69.84%UPXIUpexi0.00%+5.60%-7.11%-12.87%-73.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTXRCitius Pharmaceuticals 2.25Hold$5.00748.90% UpsideFLNACassava Sciences 2.00Hold$5.00306.50% UpsideINKTMiNK Therapeutics 2.40Hold$35.00197.72% UpsideUPXIUpexi 2.33Hold$8.10821.50% UpsideCurrent Analyst Ratings BreakdownLatest CTXR, UPXI, INKT, and FLNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026UPXIUpexi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$2.00 ➝ $1.306/24/2026CTXRCitius Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/22/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026CTXRCitius Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/18/2026CTXRCitius Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.005/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTXRCitius Pharmaceuticals$5.61M2.88N/AN/A$4.29 per share0.14FLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/AUPXIUpexi$15.81M3.91N/AN/A$1.01 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTXRCitius Pharmaceuticals-$37.43M-$2.13N/AN/AN/AN/A-61.09%-35.36%8/11/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/AINKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)UPXIUpexi-$13.68M-$0.62N/AN/AN/A-874.00%-66.70%-19.56%9/2/2026 (Estimated)Latest CTXR, UPXI, INKT, and FLNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q2 2026CTXRCitius Pharmaceuticals-$0.2808-$0.95-$0.6693-$0.95$10.23 millionN/A5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/12/2026Q3 2026UPXIUpexi-$0.20-$1.67-$1.47-$1.67$2.90 million$1.05 million5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTXRCitius PharmaceuticalsN/A0.580.16FLNACassava SciencesN/A2.192.19INKTMiNK TherapeuticsN/A1.381.38UPXIUpexi2.961.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTXRCitius Pharmaceuticals16.88%FLNACassava Sciences38.05%INKTMiNK Therapeutics2.87%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipCTXRCitius Pharmaceuticals4.99%FLNACassava Sciences4.60%INKTMiNK Therapeutics20.40%UPXIUpexi9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTXRCitius Pharmaceuticals2027.45 million26.08 millionOptionableFLNACassava Sciences2048.31 million46.09 millionOptionableINKTMiNK Therapeutics304.98 million3.97 millionNo DataUPXIUpexi13070.26 million63.94 millionOptionableCTXR, UPXI, INKT, and FLNA HeadlinesRecent News About These CompaniesUpexi Inc: Upexi Partners with Blueprint to Stake Solana Treasury AssetsJune 30, 2026 | finanznachrichten.deUpexi Partners with Blueprint to Stake Solana Treasury AssetsJune 30, 2026 | globenewswire.comUpexi Added to Russell Microcap Index in June 2026 ReconstitutionJune 26, 2026 | quiverquant.comQUpexi Added to the Russell Microcap® IndexJune 26, 2026 | globenewswire.comUpexi, Inc. Announces Pricing of ~$19.5 Million Private Placement of Common StockJune 22, 2026 | globenewswire.comUpexi Shareholders Reelect Board and Ratify AuditorJune 16, 2026 | tipranks.comUPXI Share News TodayMay 19, 2026 | uk.investing.comUpexi (UPXI) Stock Forecast & Price TargetMay 15, 2026 | investing.comUpexi Stock Short Interest Report | NASDAQ:UPXI | BenzingaMay 15, 2026 | benzinga.comUpexi (UPXI) Q3 2026 Earnings TranscriptMay 15, 2026 | fool.comUpexi, Inc. Earnings Call Highlights Crypto-Fueled VolatilityMay 13, 2026 | tipranks.comUpexi Net Loss Balloons to $109 Million on Solana Treasury MarkdownMay 13, 2026 | finance.yahoo.comUpexi Reports Fiscal Third Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comUpexi Q3 2026 earnings previewMay 11, 2026 | msn.comUpexi to Present at the LD Micro Invitational XVI Conference on May 17-19May 7, 2026 | globenewswire.comUpexi Provides Periodic Update to its Share Repurchase ProgramMay 6, 2026 | globenewswire.comUpexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ETMay 5, 2026 | globenewswire.comUpexi to Participate in the Scottsdale Capital Event on April 10-12March 31, 2026 | globenewswire.comUpexi to Participate in Upcoming March Investor ConferencesMarch 3, 2026 | globenewswire.comUpexi Earnings Call: Growth Surges, Losses MountFebruary 15, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTXR, UPXI, INKT, and FLNA Company DescriptionsCitius Pharmaceuticals NASDAQ:CTXR$0.59 +0.01 (+2.51%) As of 11:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Cassava Sciences NASDAQ:FLNA$1.23 0.00 (0.00%) As of 10:55 AM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.MiNK Therapeutics NASDAQ:INKT$11.76 +0.09 (+0.74%) As of 11:11 AM Eastern This is a fair market value price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Upexi NASDAQ:UPXI$0.88 0.00 (-0.11%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
